Technical Analysis for PTCT - PTC Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 7.79% | |
| Gapped Up | Strength | 7.79% | |
| Wide Bands | Range Expansion | 6.03% | |
| Wide Bands | Range Expansion | 4.22% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 8.24% | |
| NR7 | Range Contraction | 8.24% | |
| Narrow Range Bar | Range Contraction | 8.24% | |
| Inside Day | Range Contraction | 8.24% | |
| Wide Bands | Range Expansion | 8.24% | |
| Down 3 Days in a Row | Weakness | 8.24% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 12 minutes ago |
| Rose Above Previous Day's High | about 3 hours ago |
| 1.5x Volume Pace | about 3 hours ago |
| Gap Up Partially Closed | about 3 hours ago |
| Gapped Up (Partial) | about 3 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 04/26/2024
PTC Therapeutics, Inc. Description
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Infectious Diseases Neurological Disorders Dystrophy Gene Expression Muscular Dystrophy Cystic Fibrosis Neurodegenerative Disorders Transcription Spinal Muscular Atrophy Genzyme Neuromuscular Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 59.75 |
| 52 Week Low | 17.53 |
| Average Volume | 854,390 |
| 200-Day Moving Average | 28.26 |
| 50-Day Moving Average | 29.19 |
| 20-Day Moving Average | 29.65 |
| 10-Day Moving Average | 32.29 |
| Average True Range | 1.67 |
| RSI (14) | 55.75 |
| ADX | 29.82 |
| +DI | 29.49 |
| -DI | 17.14 |
| Chandelier Exit (Long, 3 ATRs) | 30.47 |
| Chandelier Exit (Short, 3 ATRs) | 28.99 |
| Upper Bollinger Bands | 36.37 |
| Lower Bollinger Band | 22.92 |
| Percent B (%b) | 0.61 |
| BandWidth | 45.36 |
| MACD Line | 1.13 |
| MACD Signal Line | 1.04 |
| MACD Histogram | 0.0837 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 34.46 | ||||
| Resistance 3 (R3) | 34.74 | 33.94 | 33.91 | ||
| Resistance 2 (R2) | 33.94 | 33.11 | 33.80 | 33.73 | |
| Resistance 1 (R1) | 32.56 | 32.59 | 32.16 | 32.27 | 33.55 |
| Pivot Point | 31.75 | 31.75 | 31.55 | 31.61 | 31.75 |
| Support 1 (S1) | 30.38 | 30.92 | 29.97 | 30.09 | 28.81 |
| Support 2 (S2) | 29.57 | 30.40 | 29.43 | 28.63 | |
| Support 3 (S3) | 28.19 | 29.57 | 28.45 | ||
| Support 4 (S4) | 27.90 |
